ClinicalTrials.gg
CompletedNCT00645918GRAVITASUpdated Jun 16, 2011

GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety

An interventional study of clopidogrel and placebo in Coronary Arteriosclerosis and Acute Coronary Syndrome, sponsored by Accumetrics, Inc.. Completed at 82 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-16.

Sponsored by Accumetrics, Inc. · Not applicable and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,800
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 71 studies testing clopidogrel in Coronary Artery Disease — 3 open to participants now, 3 under way, 1 of them phase 3. Clopidogrel · Coronary Artery Disease.

Enrollment
8th of 71
2,800 · median 120
Started
2008
with 8 others
No phase
6 of 71
none open now
Registered
11th of 71
by date
Lead sponsor
1 of 71
Accumetrics, Inc.

Among the 71 studies testing clopidogrel in Coronary Artery Disease, this one is the 8th largest by enrollment, is one of 9 that started in 2008, is one of 6 with no phase, and was the 11th registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

3 of the 71 studies testing clopidogrel in Coronary Artery Disease are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About clopidogrel

Clopidogrel: first FDA approval 1997 (PLAVIX), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies testing clopidogrel in Coronary Artery Disease, or all of them as a file.
02

Study summary

The objective of the GRAVITAS trial is to determine whether tailored anti-platelet therapy using the Accumetrics VerifyNow P2Y12 assay reduces major adverse cardiovascular events after drug-eluting stent implantation.

03

Conditions studied

  • Coronary Arteriosclerosis
  • Acute Coronary Syndrome

Keywords

  • Platelets
  • Platelet Function Tests
  • Clopidogrel
  • Drug Eluting Stents
  • Acute Coronary Syndrome
  • Myocardial Ischemia
  • Stent Thrombosis
  • Heart Diseases
  • Coronary Disease
  • Arterial Occlusive Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Males or females aged 18 years or older.
    1. Patients undergoing coronary angiography and possible PCI with planned use of at least one drug-eluting stent (DES), and without planned use of glycoprotein IIb/IIIa inhibitors. One or more bare metal stents (BMS) may be implanted, and other lesions may be treated without stenting, as long as at least one DES is implanted. However, the procedure must be successful and uncomplicated for all lesions (DES + BMS + non stent).
  • Indication for the procedure may be stable angina or ischemia, unstable angina, non-ST elevation MI (NSTEMI), or ST elevation MI (STEMI).
  • Have the ability to understand the requirements of the study, including consent for use and disclosure of research-related health information.
  • Have the ability to comply with study procedures and protocol, including required study visits.
    1. A female patient is eligible to enter the study if she is (1) of and not pregnant or nursing; (2) not of child-bearing potential (i.e., has had a hysterectomy, have both ovaries removed, has tubal ligation, or are , defined as 24 months without menses).

Exclusion Criteria: Pre-PCI

  • PCI within previous 30 days.
  • Prior consent to participate in GRAVITAS and not randomized by IVRS.
  • History of gastro-intestinal bleeding within 6 months.
  • Major non-cardiac surgery within 6 weeks.
  • Ischemic stroke within 6 weeks.
  • Any history of hemorrhagic stroke or sub-arachnoid hemorrhage.
  • Other bleeding diathesis, or considered by investigator to be at high-risk for bleeding on long-term clopidogrel therapy.
  • Minor surgical procedures that require cessation of dual anti therapy and result in significant bleeding are NOT eligible.
  • Current or planned therapy with coumadin anticoagulation.
  • Current or planned therapy with other thienopyridine class of ADP receptor inhibitors (e.g., prasugrel, ticlopidine), or the non-thienopyridine ticagrelor.
  • Severe allergy to stainless steel, contrast dye, unfractionated heparin, low molecular weight heparin, or bivalirudin that cannot be adequately pre-medicated.
  • Allergy to aspirin or clopidogrel.
  • Current enrollment in an drug or device study that has not reached the time period of the primary endpoint.
  • Have received GPIIb/IIIa inhibitors eptifibatide or tirofiban within 24 hours before or during PCI or abciximab within 10 days before or during PCI.
  • Thrombocytopenia (defined as platelet count \< 100 K).
  • Anemia (hematocrit \< 30%).
  • Polycythemia (hematocrit > 52%).
  • Patients unwilling or unable to complete clinical follow-up for the duration of the study.

Exclusion Criteria: Post-PCI

  • PCI with placement of at least one DES is not performed.
  • Planned staged PCI in the next 6 months post-procedure.
  • Unsuccessful PCI (post-procedure diameter stenosis >30% with less than TIMI-3 flow in any treated vessel).
  • Patients with in-hospital STEMI confirmed by prior to randomization or those whom require a target vessel revascularization of the index lesion prior to randomization.
  • Patients with acute stent thrombosis before Accumetrics VerifyNow tests.
  • Administration of any GPIIb/IIIa during PCI procedure or prior to initial hospital discharge.
  • Failure to meet clopidogrel requirements
  • Major complication during or after PCI
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
2,800 participants (actual)

Study arms

  • Active comparator
    A

    "Tailored" clopidogrel regimen - an additional clopidogrel 600-mg loading dose (eight 75-mg tablets taken orally; daily 150 mg clopidogrel dose plus additional 450 mg clopidogrel) on the day of randomization and then 150-mg clopidogrel every day thereafter for 6 months.

    Drug: clopidogrel

  • Placebo comparator
    B

    "Standard" clopidogrel regimen - a placebo loading dose (six placebo tablets taken orally plus daily dose of one placebo tablet plus 75 mg clopidogrel) on the day of randomization followed by one placebo tablet plus 75 mg clopidogrel every day thereafter for 6 months.

    Drug: clopidogrel · Drug: placebo

  • Placebo comparator
    C

    Responders: A random sample of clopidogrel responders treated with a placebo loading dose (six placebo tablets taken orally plus daily dose of one placebo tablet plus 75 mg clopidogrel) on the day of randomization followed by one placebo tablet plus 75 mg clopidogrel every day thereafter for 6 months.

    Drug: clopidogrel · Drug: placebo

Interventions

  • oral, 75 mg daily for 6 months starting on day of randomization

  • Drugplacebo

    oral, 6 pill loading dose on day of randomization; one pill daily for 6 months starting on day of randomization

  • oral, 450 mg loading dose on day of randomization; 75 mg daily for 6 months starting on day of randomization

06

What researchers measure

Primary outcomes

  1. Time to first occurrence of post-randomization CV death, non-fatal MI, or ARC definite/probable stent thrombosis in non-responders randomized to standard vs. tailored dosage

    Time frame: 6 months

Secondary outcomes

  1. Time to first occurrence of post-randomization CV death, non-fatal MI, or ARC definite/probable stent thrombosis in non-responders randomized to standard dosage vs. responders

    Time frame: 6 months

07

Study locations

82 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Scottsdale Health Care - Osborn Campus
    Scottsdale, Arizona 85258, United States
  • Scottsdale Health Care - Shea Campus
    Scottsdale, Arizona 85258, United States
  • Scripps Green Hospital
    La Jolla, California 92037, United States
  • El Camino Hospital
    Mountain View, California 94040, United States
  • UC Davis Medical Center
    Sacramento, California 95817, United States
  • Sacramento Heart and Vascular Research Center
    Sacramento, California 95825, United States
  • UCSD Medical Center
    San Diego, California 92103, United States
  • Alvarado Hospital
    San Diego, California 92120, United States
  • San Francisco General Hospital
    San Francisco, California 94110, United States
  • UCSF Moffitt-Long Hospital
    San Francisco, California 94143, United States
  • Santa Barbara Cottage Hospital
    Santa Barbara, California 93105, United States
  • Torrance Memorial Medical Center
    Torrance, California 90503, United States
  • Bridgeport Hospital
    Bridgeport, Connecticut 06610, United States
  • Danbury Hospital
    Danbury, Connecticut 06810, United States
  • Christiana Care Hospital
    Newark, Delaware 19718, United States
  • Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • Clearwater Cardiovascular and Interventional Consultants
    Clearwater, Florida 33756, United States
  • University of Florida Health Science Center
    Jacksonville, Florida 32209, United States
  • Cardiology Research Associates
    Ormond Beach, Florida 32174, United States
  • Tallahassee Memorial Hospital
    Tallahassee, Florida 32308, United States
  • St. Joseph's Research Institute
    Atlanta, Georgia 30342, United States
  • Redmond Regional Medical Center
    Rome, Georgia 30165, United States
  • Jesse Brown VA Medical Center
    Chicago, Illinois 60612, United States
  • University of Illinois Medical Center
    Chicago, Illinois 60612, United States
  • Trinity Medical Center
    Moline, Illinois 61265, United States
  • Prairie Education & Research Cooperative
    Springfield, Illinois 62701, United States
  • St. Vincent Heart Center of Indiana/The Care Group LLC
    Indianapolis, Indiana 46290, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70232, United States
  • Union Memorial Hospital
    Baltimore, Maryland 21218, United States
  • Washington Adventist Hospital
    Takoma Park, Maryland 20912, United States
  • Boston University Medical Center
    Boston, Massachusetts 02118, United States
  • The Lahey Clinic
    Burlington, Massachusetts 01803, United States
  • Baystate Medical Center
    Springfield, Massachusetts 01199, United States
  • Cardiac and Vascular Research Center of Northern Michigan
    Petoskey, Michigan 49770, United States
  • William Beaumont Hospital
    Royal Oak, Michigan 48073, United States
  • St. Joseph's Mercy Hospital
    Ypsilanti, Michigan 48197, United States
  • St. Mary's Duluth Clinic Health System
    Duluth, Minnesota 55805, United States
  • St. Luke's / Mid America Heart Institute
    Kansas City, Missouri 64111, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Lenox Hill Hospital
    New York, New York 10021, United States
  • NY Presbyterian / Weill Cornell Medical Center
    New York, New York 10021, United States
  • Hudson Valley Heart Center
    Poughkeepsie, New York 12601, United States
  • Stony Brook University Medical Center
    Stony Brook, New York 11794, United States
  • Durham VA Medical Center
    Durham, North Carolina 27705, United States
  • Carolina Cardiology Associates
    High Point, North Carolina 27262, United States
  • Wake Heart Research
    Raleigh, North Carolina 27610, United States
  • Wake Forest University
    Winston-Salem, North Carolina 27157, United States
  • The Lindner Clinical Trial Center
    Cincinnati, Ohio 45219, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • North Ohio Research, Ltd.
    Elyria, Ohio 44035, United States
  • Cleveland Cardiovascular Research Foundation
    Fairview Park, Ohio 44126, United States
  • University of Oklahoma Health Science Center
    Oklahoma City, Oklahoma 73104, United States
  • Oklahoma Cardiovascular Associates
    Oklahoma City, Oklahoma 73120, United States
  • Geisinger Clinic - Cardiology
    Danville, Pennsylvania 17822, United States
  • St. Vincent Health Center
    Erie, Pennsylvania 16502, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Geisinger Wyoming Valley Medical Center
    Wilkes-Barre, Pennsylvania 18711, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • The Miriam Hospital
    Providence, Rhode Island 02906, United States
  • AnMed Health
    Anderson, South Carolina 29621, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Black Hills Clinical Research Center
    Rapid City, South Dakota 57701, United States
  • Centennial Medical Center
    Nashville, Tennessee 37203, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • South Austin Hospital
    Austin, Texas 78704, United States
  • Austin Heart P.A.
    Austin, Texas 78756, United States
  • Baylor Heart and Vascular Hospital
    Dallas, Texas 75226, United States
  • Plaza Medical Center of Fort Worth
    Fort Worth, Texas 76104, United States
  • The Methodist Hospital
    Houston, Texas 77030, United States
  • University Hospital San Antonio (UTHSCSA)
    San Antonio, Texas 78229, United States
  • Tomball Regional Hospital
    Tomball, Texas 77375, United States
  • Royal Alexandra Hospital
    Edmonton, Alberta, Canada
  • McMaster University
    Hamilton, Ontario, Canada
  • York PCI Group
    Newmarket, Ontario, Canada
  • University of Ottawa Heart Institute
    Ottawa, Ontario, Canada
  • St. Michael's Hospital
    Toronto, Ontario M5B 1W8, Canada
  • Centre Hospitalier de l'Université de Montréal (CHUM) Hôtel-Dieu
    Montréal, Quebec, Canada
  • Hôpital du Sacré-Coeur de Montréal
    Montréal, Quebec, Canada
  • Montréal Heart Institute
    Montréal, Quebec, Canada
  • Royal Victoria Hospital
    Montréal, Quebec, Canada
  • Hôpital Laval
    Québec, Quebec, Canada
08

References and documents

Publications

  • Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation. 2011 Sep 6;124(10):1132-7. doi: 10.1161/CIRCULATIONAHA.111.029165. Epub 2011 Aug 29. PubMed 21875913 ↗
  • Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011 Mar 16;305(11):1097-105. doi: 10.1001/jama.2011.290. Erratum In: JAMA. 2011 Jun 1;305(21);2174. Stillablower, Michael E [corrected to Stillabower, Michael E]. PubMed 21406646 ↗
  • Price MJ, Berger PB, Angiolillo DJ, Teirstein PS, Tanguay JF, Kandzari DE, Cannon CP, Topol EJ. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J. 2009 May;157(5):818-24, 824.e1. doi: 10.1016/j.ahj.2009.02.012. PubMed 19376306 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2008
First posted
Mar 28, 2008
Start
Jun 2008
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Last update
Jun 16, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00645918
Lead sponsor
Accumetrics, Inc.
First posted
Mar 28, 2008
Start date
Jun 2008
Primary completion
Oct 2010
Completion
Oct 2010
Last update
Jun 16, 2011

Study contacts

Matthew J Price, M.D.
principal investigator · Scripps Advanced Clnical Trials

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clopidogrel

Start the discussion